Maximilian Schmeding

ORCID: 0000-0002-8547-287X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Liver Disease and Transplantation
  • Organ Transplantation Techniques and Outcomes
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Hepatitis C virus research
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Renal Transplantation Outcomes and Treatments
  • Gallbladder and Bile Duct Disorders
  • S100 Proteins and Annexins
  • Peptidase Inhibition and Analysis
  • Erythropoietin and Anemia Treatment
  • Organ Donation and Transplantation
  • Liver Diseases and Immunity
  • Liver physiology and pathology
  • Cardiac, Anesthesia and Surgical Outcomes
  • Protease and Inhibitor Mechanisms
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Nanoparticle-Based Drug Delivery
  • 3D Printing in Biomedical Research
  • Intraperitoneal and Appendiceal Malignancies
  • Viral-associated cancers and disorders
  • Transplantation: Methods and Outcomes
  • Hepatitis B Virus Studies
  • Ultrasound and Hyperthermia Applications

Klinikum Dortmund
2017-2025

University Hospital Carl Gustav Carus
2025

University Medical Center Freiburg
2025

Medical University of Graz
2025

University Hospital Magdeburg
2025

University of Freiburg
2025

Witten/Herdecke University
2025

RWTH Aachen University
2010-2021

Universitätsklinikum Aachen
2010-2021

Charité - Universitätsmedizin Berlin
2005-2011

BackgroundThe best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question whether perioperative chemotherapy preferable to preoperative chemoradiotherapy.MethodsIn this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients with receive FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) plus surgery or chemoradiotherapy (radiotherapy at dose of 41.4 Gy carboplatin paclitaxel) surgery. Eligibility criteria...

10.1056/nejmoa2409408 article EN New England Journal of Medicine 2025-01-22

The recurrence of liver fibrosis after transplantation (LT) for hepatitis C virus (HCV) infection is responsible graft loss and patient mortality. Although the contribution immune system to anticipated, systematic studies evaluating parameters as predictive markers allograft are lacking. infiltration cells into governed by chemokines. Here we assessed value serum levels chemokines [chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, chemokine (C-C 2 (CCL2)] with respect LT in 90...

10.1002/hep.24098 article EN Hepatology 2010-12-06

Human recombinant erythropoietin (Epo) has recently been shown to be a potent protector of ischemic damage in various organ systems. A significant reduction stroke injury following cerebral ischemia postulated as well improved cardiomyocyte function after myocardial infarction tissue pretreated with Epo. It was the aim this study evaluate effects Epo liver ischemia.Rats were subjected 45 min warm hepatic ischemia. Animals either 1,000 IU three doses or received into portal vein 30 before...

10.1159/000101009 article EN European Surgical Research 2007-01-01

Background. Calcineurin inhibitors (CNIs) play the key role in immunosuppressive protocols yet are often associated with numerous side effects. Renal insufficiency, hypertension, hyperglycemia, and increased risk of secondary malignancy major problems short- long-term follow-up liver transplant patients. Mycophenolate mofetil (MMF) has proved to be a potent agent free CNI-associated Patients Methods. One hundred fifty patients who received transplantation at our institution (1998–2003) were...

10.1097/tp.0b013e31822d880d article EN Transplantation 2011-10-04

Today, hepatitis C virus (HCV) is the leading cause for liver transplantation (LT) and viral recurrence almost universal. It has been suggested that replication within transplanted tissue might be increased in organs of reduced size such as LD grafts. In current literature data controversial, with many studies lacking routine biopsies. We performed a retrospective analysis 289 HCV-LT (20 splits) patients receiving transplants between 1997 2005. Patient organ survival, intensity HCV...

10.1002/lt.21138 article EN Liver Transplantation 2007-01-01

Abstract Background and Aim: It has been proven in various animal studies that recombinant human erythropoietin (rHuEPO) protects renal, cardiac neuronal, as well hepatic, tissue from ischemia, promotes regeneration of adult central nervous system neurons. To date, no data are available to whether rHuEPO the ability stimulate liver after resection. Methods: Rats undergoing 70% or 90% hepatectomy received an intraportalvenous administration (i.p.) prior resection a subcutaneous injection...

10.1111/j.1440-1746.2007.05265.x article EN Journal of Gastroenterology and Hepatology 2008-07-01

BACKGROUND:Organ shortage is a major problem in liver transplantation. The use of extended criteria donors has become the most important strategy for increasing donor pool. However, role body mass index not yet been thoroughly investigated. aim our study was to compare outcomes after transplantation patients who received from with BMI <30, 30–39, and ≥40, special regard incidence early allograft dysfunction (EAD) primary non-function (PNF). MATERIAL AND METHODS:One hundred sixty-three...

10.12659/aot.896101 article EN Annals of Transplantation 2016-03-31

Fibrosis recurrence after liver transplantation (LT) for hepatitis C virus (HCV) is a universal event and strongly determines patient's prognosis. The recipient risk factors fibrosis are still poorly defined. Here we assess genetic score as predictor of LT. cirrhosis (CRS), which comprises allele variants in 7 genes (adaptor-related protein complex 3 S2, aquaporin 2, antizyme inhibitor 1, degenerative spermatocyte homolog 1 lipid desaturase, syntaxin binding 5-like, toll-like receptor 4,...

10.1002/lt.22475 article EN Liver Transplantation 2011-12-05

Abstract Background Sarcopenia, obesity and sarcopenic have been linked to impaired outcome after liver surgery. Preoperative function of sarcopenic, obese sarcopenic‐obese patients might be reduced, possibly leading more post‐operative morbidity. The aim this study was explore whether volume were influenced by body composition in undergoing resection. Methods In 2011 2012, all consecutive the methacetin breath test included. Liver volumetry muscle mass analysis performed using preoperative...

10.1002/jcsm.12018 article EN cc-by-nc Journal of Cachexia Sarcopenia and Muscle 2015-04-28
Coming Soon ...